<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Molecular Medicine Reports</journal-id>
<journal-title-group>
<journal-title>Molecular Medicine Reports</journal-title></journal-title-group>
<issn pub-type="ppub">1791-2997</issn>
<issn pub-type="epub">1791-3004</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/mmr.2016.5622</article-id>
<article-id pub-id-type="publisher-id">mmr-14-04-3490</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>C-reactive protein/oxidized low density lipoprotein/&#x003B2;2-glycoprotein I complexes induce lipid accumulation and inflammatory reaction in macrophages via p38/mitogen-activated protein kinase and nuclear factor-&#x003BA;B signaling pathways</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Wang</surname><given-names>Jie</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>Feng</surname><given-names>Mei-Jun</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>Zhang</surname><given-names>Rui</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>Yu</surname><given-names>De-Min</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>Zhou</surname><given-names>Sai-Jun</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>Chen</surname><given-names>Rui</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>Yu</surname><given-names>Pei</given-names></name><xref ref-type="corresp" rid="c1-mmr-14-04-3490"/></contrib>
<aff id="af1-mmr-14-04-3490">2011 Collaborative Innovation Center of Tianjin For Medical Epigenetics, The Key Laboratory of Hormones and Development, Ministry of Health, Metabolic Diseases Hospital &amp; Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300070, P.R. China</aff></contrib-group>
<author-notes>
<corresp id="c1-mmr-14-04-3490">Correspondence to: Professor Pei Yu, 2011 Collaborative Innovation Center of Tianjin For Medical Epigenetics, The Key Laboratory of Hormones and Development, Ministry of Health, Metabolic Diseases Hospital &amp; Tianjin Institute of Endocrinology, Tianjin Medical University, 66 Tong'an Street, Heping, Tianjin 300070, P.R. China, E-mail: <email>peiyu@tmu.edu.cn</email></corresp></author-notes>
<pub-date pub-type="ppub">
<month>10</month>
<year>2016</year></pub-date>
<pub-date pub-type="epub">
<day>11</day>
<month>08</month>
<year>2016</year></pub-date>
<volume>14</volume>
<issue>4</issue>
<fpage>3490</fpage>
<lpage>3498</lpage>
<history>
<date date-type="received">
<day>30</day>
<month>11</month>
<year>2014</year></date>
<date date-type="accepted">
<day>17</day>
<month>08</month>
<year>2015</year></date></history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2016, Spandidos Publications</copyright-statement>
<copyright-year>2016</copyright-year></permissions>
<abstract>
<p>Oxidized low-density lipoprotein (oxLDL) can bind to &#x003B2;2-glycoprotein I (&#x003B2;2GPI) and C-reactive protein (CRP) to form stable complexes, which exert certain effects in diabetic cardiovascular disease. A previous study by our group has confirmed that the resulting complexes promote atherosclerosis in diabetic BALB/c mice. The present study was designed to investigate the effects and potential mechanisms of oxLDL complexes on lipid accumulation and inflammatory reactions in RAW264.7 macrophages cultured in a hyperglycemic environment. Cultured cells were divided into seven groups, which were treated with phosphate-buffered saline (control), CRP, &#x003B2;2GPI, oxLDL, CRP/oxLDL, oxLDL/&#x003B2;2GPI or CRP/oxLDL/&#x003B2;2GPI. The results revealed the formation of foam cells in the oxLDL, CRP/oxLDL, oxLDL/&#x003B2;2GPI as well as CRP/oxLDL/&#x003B2;2GPI groups. Compared with oxLDL, the three complexes induced less lipid accumulation (P&lt;0.05) through inhibiting the expression of CD36 mRNA and promoting the expression of and ABCG1 mRNA (P&lt;0.05 vs. oxLDL). Furthermore, the levels of inflammatory factors interleukin (IL)-1&#x003B2;, IL-6 and tumor necrosis factor-&#x003B1; were elevated in the CRP/oxLDL and CRP/oxLDL/&#x003B2;2GPI groups (P&gt;0.05 vs. oxLDL), and obvious effects on p38/mitogen-activated protein kinase and nuclear factor (NF)-&#x003BA;B phosphorylation were also observed in these groups (P&lt;0.05 vs. oxLDL). These results suggested that CRP/oxLDL/&#x003B2;G2P1 complexes may induce lipid accumulation and inflammation in macrophages via the p38/MAPK and NF-&#x003BA;B signaling pathways. However, some differences were observed between the complexes, which may be attributed to the property of each constituent; therefore, further studies are required.</p></abstract>
<kwd-group>
<kwd>C-reactive protein</kwd>
<kwd>oxidized low density lipoprotein</kwd>
<kwd>&#x003B2;2-glycoprotein I</kwd>
<kwd>macrophage</kwd>
<kwd>foam cell</kwd>
<kwd>inflammatory response</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Atherosclerosis (AS) is a multifactorial pathological process of arterial vasculature undergoing gradual intima thickening, causing decreased elasticity and narrowing. The causal association between AS and cholesterol metabolism is well established. The appearance of lipid accumulation and foam cells is a characteristic histological finding in early AS lesions (<xref rid="b1-mmr-14-04-3490" ref-type="bibr">1</xref>,<xref rid="b2-mmr-14-04-3490" ref-type="bibr">2</xref>).</p>
<p>Oxidized low-density lipoprotein (oxLDL) is highly proinflammatory and has a key role in the generation and progression of AS. OxLDL binds to &#x003B2;2-glycoprotein I (&#x003B2;2GPI) and C-reactive protein (CRP), resulting in the formation of covalently stable complexes, such as CRP/oxLDL, oxLDL/&#x003B2;2GPI and CRP/oxLDL/&#x003B2;2GPI. &#x003B2;2GPI is a highly glycosylated plasma protein, which serves as the main specific antigen for anti-phospholipid antibodies associated with atherothrombotic complications frequently observed in patients with systemic autoimmune diseases (<xref rid="b3-mmr-14-04-3490" ref-type="bibr">3</xref>). OxLDL interacts with &#x003B2;2GPI via 7-ketocholesterol, which bears a w-carboxyl acyl chain, to form a covalent oxLDL/&#x003B2;2GPI complex (<xref rid="b4-mmr-14-04-3490" ref-type="bibr">4</xref>,<xref rid="b5-mmr-14-04-3490" ref-type="bibr">5</xref>). CRP is an acute-phase reactant that has a major role in innate immunity and inflammation. Multiple clinical studies have demonstrated the predictive value of increased CRP levels for atherothrombotic events, suggesting that CRP is a serological marker for AS (<xref rid="b6-mmr-14-04-3490" ref-type="bibr">6</xref>). CRP is able to bind to oxLDL but not to native LDL through the recognition of a phosphorylcholine moiety in oxLDL (<xref rid="b7-mmr-14-04-3490" ref-type="bibr">7</xref>).</p>
<p>Accumulating evidence suggested the participation of these complexes in AS-associated processes (<xref rid="b8-mmr-14-04-3490" ref-type="bibr">8</xref>,<xref rid="b9-mmr-14-04-3490" ref-type="bibr">9</xref>). In auto-immune diseases, such as anti-phospholipid syndrome (APS), oxLDL/&#x003B2;2GPI and its antibody were found in the intima of AS lesions and the specific immune complexes were taken up avidly by macrophages via anti-&#x003B2;2GPI auto-antibody-mediated phagocytosis (<xref rid="b8-mmr-14-04-3490" ref-type="bibr">8</xref>). However, in the serum of diabetics, anti-&#x003B2;2GPI auto-antibody levels were found to be low (<xref rid="b10-mmr-14-04-3490" ref-type="bibr">10</xref>), while oxLDL/&#x003B2;2GPI, CRP/oxLDL and CRP/oxLDL/&#x003B2;2GPI complexes were present at high concentrations and were all positively correlated with the thickness of the intima media, a sensitive index for cardiovascular disease (<xref rid="b11-mmr-14-04-3490" ref-type="bibr">11</xref>). Direct evidence for the involvement of CRP and &#x003B2;2GPI in AS was provided by immunohistochemical staining, which demonstrated the presence of CRP as well as &#x003B2;2GPI co-localized with oxLDL in human AS lesions (<xref rid="b12-mmr-14-04-3490" ref-type="bibr">12</xref>). A previous study by our group reported that the CRP/oxLDL/&#x003B2;2GPI complex aggravated AS progression in diabetic BALB/c mice, which may be mediated through the p38/mitogen-activated protein kinase (MAPK) pathway (<xref rid="b9-mmr-14-04-3490" ref-type="bibr">9</xref>). However, <italic>in vitro</italic>, the roles of these oxLDL complexes in the onset and development of AS in diabetes have not been elucidated. The present study aimed to investigate the impact of various oxLDL complexes on lipid accumulation and inflammatory reactions in RAW264.7 macrophages under hyperglycemic conditions.</p></sec>
<sec sec-type="methods">
<title>Materials and methods</title>
<sec>
<title>Materials and reagents</title>
<p>The RAW264.7 mouse macrophage cell line was purchased from the American Type Culture Collection (ATCC no TIB-71; Manassas, VA, USA). Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum (FBS) were purchased from Beijing Solarbio Science &amp; Technology Co., Ltd. (Beijing, China). oxLDL was purchased from XINYUANJIAHE Biotechnology Co., Ltd. (Beijing, China). CRP was purchased from ProSpec (cat no. pro-557; Rehovot, Israel). Oil Red O and hematoxylin were purchased from Sigma-Aldrich (St. Louis, MO, USA). An intracellular total cholesterol assay kit was purchased from Applygen Techonology Co., Ltd (Beijing, China). Interleukin (IL)-1&#x003B2;, IL-6 and tumor necrosis factor (TNF)-&#x003B1; ELISA kits were purchased from Uscn Life Science Inc. (Hubei, China). The TRIzol reagent, RevertAid&#x02122; First Strand cDNA Synthesis kit and Micro Bicinchoninc Acid (BCA) Protein Assay kit were purchased from Invitrogen Life Technologies, Inc. (Carlsbad, CA, USA). SYBR<sup>&#x000AE;</sup> Premix Ex TaqTM DNA polymerase were purchased from Takara Bio. Inc. (Otsu, Japan). Rabbit monoclonal antibodies to p38/MAPK, phosphorylated (p)-p38MAPK (Thr180/Tyr182), nuclear factor (NF)-&#x003BA;B (p65) and p-NF-&#x003BA;B (Ser 276) were purchased from Cell Signaling Technology, Inc. (Beverly, MA, USA). Mouse monoclonal antibody to &#x003B2;-actin and horseradish peroxidase (HRP)-labeled goat anti-rabbit and anti-mouse immunoglobulin (Ig)G antibody were purchased from Tianjin Sungene Biotec Co., Ltd (Tianjin, China). High-performance chemiluminescence kit was purchased from Beijing ComWin Biotech Co., Ltd. (Beijing, China).</p></sec>
<sec>
<title>Purification of &#x003B2;2GPI</title>
<p>&#x003B2;2GPI was purified from normal human plasma as described previously (<xref rid="b9-mmr-14-04-3490" ref-type="bibr">9</xref>). The blood was donated by a healthy voluntary blood donor at the Metabolic Diseases Hospital of Tianjin Medical University (Tianjin, China) in April 2014. The present study was approved by the ethics committee of Metabolic Diseases Hospital fo Tianjin Medical University. Written informed consent was obtained form the healthy blood donor. Plasma &#x003B2;2GPI was precipitated using 3% (v/v) perchloric acid (Sigma-Aldrich) and isolated by Heparin-Sepharose affinity chromatography (HiTrap Heparin; GE Healthcare, Little Chalfont, UK). Liquid Chromatography-Mass Spectrometric analysis (1100LC/MSD; Agilent Technologies, Santa Clara, CA, USA) was used to confirm this protein. The purity of &#x003B2;2GPI was confirmed by SDS-PAGE using a 10% Tris-glycine gel. The SDS-PAGE analysis of the protein sample showed an identical band to that of the standard &#x003B2;2GPI sample (Crystal Chem, Inc., Downers Grove, IL, USA). The purified &#x003B2;2GPI was tested to exclude the possibility of lipopolysaccharide contamination using the Limulus ES-II Test (<xref rid="b13-mmr-14-04-3490" ref-type="bibr">13</xref>,<xref rid="b14-mmr-14-04-3490" ref-type="bibr">14</xref>). Briefly, 250 <italic>&#x000B5;</italic>g human &#x003B2;2GPI was incubated with an extraction solution of chloroform/methanol (2:1) for 2 h at 25&#x000B0;C with constant mixing on a rotator. Following centrifugation, the aqueous supernatant containing lipid-free &#x003B2;2GPI was retained. All treated preparations were sterilized using a 0.2 <italic>&#x000B5;</italic>m filter and tested for endotoxin activity using a commercial Limulus amebocyte lysate assay (Associates of Cape Cod, Inc., East Falmouth, MA, USA), according to the manufacturer's protocol. The lower limit of endotoxin detection of the LAL assay was 0.005 endotoxin units/ml. The BCA method was used to determine the concentration of &#x003B2;2GPI.</p></sec>
<sec>
<title>Complex preparation and identification</title>
<p>The preparation of CRP/oxLDL, oxLDL/&#x003B2;2GPI and CRP/oxLDL/&#x003B2;2GPI complexes was performed as described previously (<xref rid="b9-mmr-14-04-3490" ref-type="bibr">9</xref>,<xref rid="b11-mmr-14-04-3490" ref-type="bibr">11</xref>,<xref rid="b15-mmr-14-04-3490" ref-type="bibr">15</xref>). Briefly, CRP/oxLDL and oxLDL/&#x003B2;2GPI complexes were pre-formed by incubating oxLDL &#x0005B;1 mg apolipoprotein B (apoB) equivalent/ml&#x0005D; and &#x003B2;2GPI (1 mg/ml) in the absence of CaCl<sub>2</sub>, as well as oxLDL (1 mg apoB equivalent/ml) and CRP (1 mg/ml) in the presence of 2 mM CaCl<sub>2</sub>, at 37&#x000B0;C for 16 h. Subsequently, the purified oxLDL/&#x003B2;2GPI (1 mg/ml of apoB equivalent) was further incubated with CRP (0.1 mg/ml) in the presence of 2 mM CaCl<sub>2</sub> at 37&#x000B0;C for another 16 h to form the covalent CRP/oxLDL/&#x003B2;2GPI complex. The identity of the oxLDL/&#x003B2;2GPI, CRP/oxLDL and CRP/oxLDL/&#x003B2;2GPI complexes was confirmed by ELISAs as described previously (<xref rid="b9-mmr-14-04-3490" ref-type="bibr">9</xref>,<xref rid="b11-mmr-14-04-3490" ref-type="bibr">11</xref>).</p></sec>
<sec>
<title>Cell culture</title>
<p>RAW264.7 macrophages were cultured in DMEM with 25 mmol/l glucose (Beijing Solarbio Science &amp; Technology Co., Ltd.), which was supplemented with 10% (v/v) FBS, 100 U/ml penicillin and 100 g/ml streptomycin at 37&#x000B0;C in a humidified incubator with 5% (v/v) CO<sub>2</sub>. Cells were seeded onto six-well or 24-well cell culture plates at a density of 1&#x000D7;10<sup>5</sup>/ml cultured for 12 h and then serum-starved for another 12 h. The cells were then incubated for another 24 h in FBS-free hyperglycemic DMEM with the following intervention factors: phosphate-buffered saline (PBS; control), 80 <italic>&#x000B5;</italic>g/ml CRP, 80 <italic>&#x000B5;</italic>g/ml &#x003B2;2GPI, 80 <italic>&#x000B5;</italic>g/ml oxLDL, 160 <italic>&#x000B5;</italic>g/ml CRP/oxLDL, 160 <italic>&#x000B5;</italic>g/ml oxLDL/&#x003B2;2GPI or 176 <italic>&#x000B5;</italic>g/ml CRP/oxLDL/&#x003B2;2GPI, which all contained the same amount of oxLDL. The concentrations and incubation time with the above reagents are based on those used in previous studies by our group (<xref rid="b9-mmr-14-04-3490" ref-type="bibr">9</xref>,<xref rid="b16-mmr-14-04-3490" ref-type="bibr">16</xref>). Following incubation, the culture medium was collected for ELISAs and the cells were washed twice with PBS prior to subsequent analysis.</p></sec>
<sec>
<title>Oil Red O staining</title>
<p>Oil Red O staining of foam cells was performed as described in a previous study by our group (<xref rid="b16-mmr-14-04-3490" ref-type="bibr">16</xref>). Briefly, the macrophages were fixed in 10% (v/v) formaldehyde solution for 30 min. Fixed cells were washed with PBS and then with 60% (v/v) isopropanol solution twice for 5 min each. Next, the cells were stained with freshly prepared Oil Red O working solution for 30 min at 60&#x000B0;C. The nuclei were lightly stained with hematoxylin for 5 min. Stained cells were washed with distilled water, mounted in neutral balsam (Beijing Solarbio Science &amp; Technology Co., Ltd.) and then observed using an inverted microscope (DM4000 B; Leica Microsystems, Wetzlar, Germany).</p></sec>
<sec>
<title>Intracellular total cholesterol content assay</title>
<p>After treatment with the complexes, the culture medium was removed and cells were washed twice with ice-cold PBS. The cells were collected and sonicated at 4&#x000B0;C in lysis buffer (1X Tris-buffered saline, pH 7.5, 10 mM EDTA, 1% Triton X-100, 10 mM NaF, 1 mM phenylmethanesulfonylfluoride, all Beijing Solarbio Science &amp; Technology Co., Ltd.; and 1 mM sodium orthovanadate, Sigma-Aldrich). After homogenization, the supernatant was obtained by centrifugation (10,000 &#x000D7;g for 10 min at 4&#x000B0;C). Protein concentrations were determined according to BCA assay. Total cholesterol levels were measured using a commercially available intracellular total cholesterol assay kit according to the manufacturer's instructions. Cholesterol levels were expressed as <italic>&#x000B5;</italic>mol per mg protein.</p></sec>
<sec>
<title>Total RNA isolation and reverse-transcription quantitative polymerase chain reaction (PCR)</title>
<p>Primers for scavenger receptor B (CD36), scavenger receptor B1 (SRB1), adenosine triphosphate (ATP) binding cassette receptor A1 (ABCA1), ATP binding cassette receptor G1 (ABCG1) and &#x003B2;-actin mRNA were designed according to the GenBank database (<ext-link xlink:href="http://www.ncbi.nlm.nih.gov/genbank/" ext-link-type="uri">http://www.ncbi.nlm.nih.gov/genbank/</ext-link>) using Primer 5.0 (Premier Biosoft, Palo Alto, CA, USA) and Oligo 6.0 (Molecular Biology Insights, Inc., Colorado Springs, CA, USA) software. The primers were purchased from Sangon Biotech Co., Ltd. (Shanghai, China). The primer sequences were as follows: CD36 forward, 5&#x02032;-GAACCACTGCTTTCAAAAACTGG-3&#x02032; and reverse, 5&#x02032;-TGCTGTTCTTTGCCACGTCA-3&#x02032;; SRB1 forward, 5&#x02032;-TTTGGAGTGGTAGTAAAAAGGGC-3&#x02032; and reverse, 5&#x02032;-TGACATCAGGGACTCAGAGTAG-3&#x02032;; ABCA1 forward, 5&#x02032;-AGTGATAATCAAAGTCAAAGGCACAC-3&#x02032; and reverse, 5&#x02032;-AGCAACTTGGCACTAGTAACTCTG-3&#x02032;; ABCG1 forward, 5&#x02032;-TTCATCGTCCTGGGCATCTT-3&#x02032; and reverse, 5&#x02032;-CGGATTTTGTATCTGAGGACGAA-3&#x02032;; &#x003B2;-actin forward, 5&#x02032;-TGGAGAAGAGCTATGAGCTGCCTG-3&#x02032; and reverse, 5&#x02032;-GTGCCACCAGACAGCACTGTGTTG-3&#x02032;.</p>
<p>Total RNA was extracted from cells using TRIzol reagent according to the manufacturer's instructions. RNA (2 <italic>&#x000B5;</italic>g) was reverse transcribed into cDNA using RevertAid&#x02122; First Strand cDNA Synthesis kit, as previously described (<xref rid="b16-mmr-14-04-3490" ref-type="bibr">16</xref>). The PCR was performed using an iQ&#x02122; Real-Time PCR Detection system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). For qPCR, each reaction comprised 5 <italic>&#x000B5;</italic>l SYBR<sup>&#x000AE;</sup> Green II (Takara Bio. Inc.), 0.4 <italic>&#x000B5;</italic>l downstream/upstream primers, 1 <italic>&#x000B5;</italic>l cDNA, and 3.2 <italic>&#x000B5;</italic>l diethylpyrocarbonate-treated water. PCR cycling conditions were as follows: 50&#x000B0;C for 2 min, 94&#x000B0;C for 3 min, followed by 40 cycles at 94&#x000B0;C for 30 sec, 60&#x000B0;C for 30 sec and 72&#x000B0;C for 20 sec. The relative quantification was based on &#x003B2;-actin to determine fold-differences in the expression of the target gene. The &#x00394;&#x00394;Ct-method was used for the normalization procedure. The final results are expressed as the 2<sup>&#x02212;&#x00394;&#x00394;Ct</sup> value between the experimental and the control group.</p></sec>
<sec>
<title>ELISA</title>
<p>RAW264.7 cells were seeded at 1&#x000D7;10<sup>5</sup>/well in a 24-well plate. After serum-starvation for 12 h, cells were treated with various reagents as described above. IL-1&#x003B2;, IL-6 and TNF-&#x003B1; were determined in the supernatants of the cells using commercially available ELISA kits according to the manufacturer's instructions. Standard samples provided in the kits were used to calculate absolute index levels. The protein levels of IL-1&#x003B2;, IL-6 and TNF-&#x003B1; in the cell culture media were expressed in pg/ml.</p></sec>
<sec>
<title>Western blot analysis</title>
<p>After treatment with the complexes as described above, the culture medium was removed and the reaction was terminated by adding 1 ml cold PBS containing 100 <italic>&#x000B5;</italic>M sodium vanadate (Sigma-Aldrich). The samples were then placed on ice, washed with ice-cold PBS and lysed in radioimmunoprecipitation (RIPA) lysis buffer for 30 min. Lysates were clarified by centrifugation at 12,000 &#x000D7; g for 15 min at 4&#x000B0;C, and the protein content in the supernatant was measured using the BCA method. 10 <italic>&#x000B5;</italic>g protein was subjected to 12% SDS-PAGE and transferred onto a nitrocellulose membrane. The membrane was blocked in freshly prepared 5% skimmed milk in Tris-buffered saline/0.05% Tween 20 (TBST) for 2 h at room temperature (RT), subsequently incubated with primary antibodies against p38/MAPK (cat. no. 14451), p-p38/MAPK (Thr180/Tyr182; cat. no. 4511), NF-&#x003BA;B (p65) (cat. no. 8242), p-NF-&#x003BA;B (Ser 276) (cat. no. 3037) (all 1:1,000) or &#x003B2;-actin (cat. no. DKM9001; 1:5,000) diluted in 5% skimmed milk - TBST, overnight at 4&#x000B0;C. Following three washes for 10 min each with TBST, the membranes were incubated with HRP-conjugated goat anti-rabbit (cat. no. LK2001) or anti-mouse (cat. no. LK2003) IgG in 5% skimmed milk - TBST (1:3,000) for 1 h at RT. The membrane was then extensively washed with TBST. The immunoreactive bands were detected using enhanced chemiluminescence reagents, blots were imaged using radiography with an ultraviolet transmission analyzer (GE Healthcare, Piscataway, NJ, USA) and images were captured onto film (Kodak, Inc., Rochester, NY, USA), and analyzed using BandScan software (Bio-Rad Gel Doc 2000; Bio-Rad Laboratories, Inc.). &#x003B2;-actin was used as the internal standard protein.</p></sec>
<sec>
<title>Statistical analysis</title>
<p>All experiments were performed at least three times in duplicate. SPSS 20.0 software (International Business Machines, Armonk, NY, USA) was used for statistical analysis. Values are expressed as the mean &#x000B1; standard deviation. Comparisons among multi-groups were accomplished by one-way analysis of variance and differences between two groups were analyzed using the Student-Newman-Keuls Test. P&lt;0.05 was considered to indicate a statistically significant difference between values.</p></sec></sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title>OxLDL and its complexes induce lipid accumulation in macrophages</title>
<p>Incubation of RAW264.7 cells with oxLDL produced lipid-rich foam cells characterized by an intense red color accompanied with an increase in cell size and a decrease in cell count. Incubation of macrophages with CRP or &#x003B2;2GPI alone did not produce any observable effects; however, in the CRP/oxLDL, oxLDL/&#x003B2;2GPI and CRP/oxLDL/&#x003B2;2GPI groups, a considerably larger amount of red lipid droplets was observed in the cytoplasm (<xref rid="f1-mmr-14-04-3490" ref-type="fig">Fig. 1</xref>).</p></sec>
<sec>
<title>OxLDL and its complexes increase the intracellular total cholesterol content in RAW264.7 macrophages</title>
<p>Among all of the groups, the total cholesterol (TC) content in cells treated with oxLDL was highest, which was 6.7-fold that of the control group (P&lt;0.05). Treatment with CRP or &#x003B2;2GPI alone produced no obvious change in the cholesterol content compared with that in the control group. The cholesterol accumulation induced by the three complexes significantly decreased in comparison to that in the oxLDL group (P&lt;0.05). TC in the CRP/oxLDL group was 5.5-fold of that in the control group, which was higher than that in the oxLDL/&#x003B2;2GPI and CRP/oxLDL/&#x003B2;2GPI groups (P&lt;0.05) and 3.1- and 4.0-fold of that in the control group, respectively. TC in the oxLDL/&#x003B2;2GPI group was lower than that in the CRP/oxLDL and CRP/oxLDL/&#x003B2;2GPI groups (P&lt;0.05) (<xref rid="tI-mmr-14-04-3490" ref-type="table">Table I</xref>).</p></sec>
<sec>
<title>oxLDL and its complexes increase CD36, SRB1, ABCA1 and ABCG1 mRNA expression in macrophages</title>
<p>Compared to that in the control group, the mRNA expression of SRB1, ABCG1, CD36 and ABCA1 in the oxLDL group was significantly increased (P&lt;0.05), which was consistent with the findings of a previous study by our group (<xref rid="b16-mmr-14-04-3490" ref-type="bibr">16</xref>). When compared to oxLDL, all of the three complexes inhibited the expression of CD36, but had no significant effect on SRB1 and ABCA1 expression (P&lt;0.05). Only oxLDL/&#x003B2;2GPI and CRP/oxLDL/&#x003B2;2GPI significantly increased the expression of ABCG1 compared to that in the oxLDL group (P&lt;0.05). However, there was no significant difference in the expression levels of CD36, SRB1, ABCA1 and ABCG1 mRNA among the three complexes (<xref rid="f2-mmr-14-04-3490" ref-type="fig">Fig. 2</xref>).</p></sec>
<sec>
<title>OxLDL and its complexes increase the secretion of inflammatory factors IL-1&#x003B2;, IL-6 and TNF-&#x003B1; by macrophages</title>
<p>As oxLDL is highly pro-inflammatory, the present study assessed its effect on the secretion of inflammatory factors IL-1&#x003B2;, IL-6 and TNF-&#x003B1; by RAW264.7 macrophages. Compared with the expression of IL-1&#x003B2;, IL-6 and TNF-&#x003B1; following treatment with CRP or &#x003B2;2GPI alone, it was significantly increased by their complexes with oxLDL. OxLDL/&#x003B2;2GPI inhibited the secretion of IL-1&#x003B2; and IL-6 induced by oxLDL (P&lt;0.05). There were no differences in the expression levels of IL-1&#x003B2; and IL-6 among the oxLDL, CRP/oxLDL and CRP/oxLDL/&#x003B2;2GPI groups (P&gt;0.05). Furthermore, there were no significant differences among the levels of TNF-&#x003B1; following treatment with oxLDL and those following treatment with any of its complexes (P&gt;0.05) (<xref rid="f3-mmr-14-04-3490" ref-type="fig">Fig. 3</xref>).</p></sec>
<sec>
<title>P38/MAPK and NF-&#x003BA;B phosphorylation in RAW264.7 macrophages</title>
<p>OxLDL and its complexes significantly triggered the phosphorylation of p38/MAPK and NF-&#x003BA;B compared with that in the control group (P&lt;0.05) (<xref rid="f4-mmr-14-04-3490" ref-type="fig">Fig. 4</xref>). The increase of p-p38/MAPK and p-NF-&#x003BA;B induced by oxLDL/&#x003B2;2GPI treatment was lower than that caused by oxLDL (P&lt;0.05). The effect of CRP/oxLDL/&#x003B2;2GPI on activating the phosphorylation of p38/MAPK and NF-&#x003BA;B was identical to that of oxLDL (P&gt;0.05). In the CRP/oxLDL group, phosphorylation of p38/MAPK and p-NF-&#x003BA;B was decreased compared with that in the oxLDL group, while only the difference in NF-&#x003BA;B phosphorylation was significant (P&lt;0.05 vs. oxLDL).</p></sec></sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>In a previous study by our group, animal experiments using BALB/c mice showed that exogenous CRP/oxLDL/&#x003B2;2GPI complexes aggravated AS in diabetic BALB/c mice by increasing lipid uptake, which was indicated to be mediated via the p38/MAPK signaling pathway (<xref rid="b9-mmr-14-04-3490" ref-type="bibr">9</xref>), while the contribution of formed auto-immune antibodies to the process could not be excluded. Given that no <italic>in vitro</italic> study has been performed to detect the different roles of oxLDL by-product complexes on foam-cell formation and inflammatory activation without the interference of antibodies, the present study aimed to investigate the effects and the potential mechanisms of CRP, oxLDL and &#x003B2;2GPI as well as their complexes CRP/oxLDL, oxLDL/&#x003B2;2GPI and CRP/oxLDL/&#x003B2;2GPI on lipid accumulation and inflammatory cytokine release in RAW264.7 macrophages.</p>
<p>A previous study by our group has established the foam cell model <italic>in vitro</italic> by stimulating murine RAW264.7 macrophages with oxLDL (<xref rid="b16-mmr-14-04-3490" ref-type="bibr">16</xref>). In the present study, CRP/oxLDL, oxLDL/&#x003B2;2GPI and CRP/oxLDL/&#x003B2;2GPI were able to induce macrophages to accumulate lipid and develop into foam cells; however, this effect was less marked than that of oxLDL alone, as confirmed by assessment of the cells' cholesterol content. The covalent binding of &#x003B2;2GPI to oxLDL reduced lipid accumulation to a significant degree, suggesting that &#x003B2;2GPI acts as an anti-AS agent in the process of foam cell formation and AS. With regard to the role of CRP/oxLDL, the present study showed that the levels of cholesterol in the CRP/oxLDL group were lower than those in the oxLDL group, which was consistent with the findings of other studies, which reported that macrophage binding/uptake of oxLDL was decreased when complexed with CRP (<xref rid="b17-mmr-14-04-3490" ref-type="bibr">17</xref>,<xref rid="b18-mmr-14-04-3490" ref-type="bibr">18</xref>). The effect of CRP/oxLDL/&#x003B2;2GPI on lipid accumulation in macrophages was lower than that of CRP/oxLDL, while being higher than that of oxLDL/&#x003B2;2GPI; however these differences were not significant. Thus, the binding of CRP or &#x003B2;2GPI to oxLDL was able to induce foam-cell formation, which was less marked than the effect of oxLDL on macrophage lipid uptake.</p>
<p>The present study further investigated the possible mechanism of lipid accumulation in macrophages. The intracellular load of oxLDL is mainly mediated by scavenger receptors, including SRBl, CD36 and lectin-like oxidized LDL receptor 1, which are expressed on the surface of macrophages, resulting in the formation of foam cells (<xref rid="b19-mmr-14-04-3490" ref-type="bibr">19</xref>). ABCA1 and ABCG1 are key participants in reverse cholesterol transport, mediating cholesterol efflux directly to high-density lipoprotein particles (<xref rid="b20-mmr-14-04-3490" ref-type="bibr">20</xref>). The results of the present study showed that oxLDL promoted the accumulation of lipids within the cells by upregulating the expression of CD36, SRB1, ABCA1 and ABCG1 mRNA. All of the three complexes promoted CD36 mRNA expression, while their effects were less marked than that of oxLDL, which is thought to have a vital role in promoting foam-cell formation. &#x003B2;2GPI was indicated to have marked anti-AS properties, as expression of CD36 mRNA in the &#x003B2;2GPI group was as low as that in the control group, and in the oxLDL/&#x003B2;2GPI group, CD36 expression was significantly reduced compared with that in the oxLDL group.</p>
<p>Given that CRP and oxLDL are potent pro-inflammatory substances, the present study analyzed the secretion levels of IL-1&#x003B2;, IL-6 and TNF-&#x003B1; by macrophage cells in order to assess their inflammatory response induced by the complexes. IL-1&#x003B2; is a potent pro-inflammatory and atherogenic cytokine (<xref rid="b21-mmr-14-04-3490" ref-type="bibr">21</xref>,<xref rid="b22-mmr-14-04-3490" ref-type="bibr">22</xref>); in addition, macrophages are the primary IL-6 and TNF-&#x003B1;-producing cells. In the present study, the secretion of IL-1&#x003B2; and IL-6 in the oxLDL/&#x003B2;2GPI group was reduced compared with that in the oxLDL group. The decreased inflammatory effect of oxLDL/&#x003B2;2GPI implied that &#x003B2;2GPI binds to oxLDL, mitigating its harmful inflammatory impact and possibly exerting a protective effect in the process of foam-cell formation and AS. However, a previous <italic>in vivo</italic> study by our group showed that oxLDL/&#x003B2;2GPI increased pro-inflammatory cytokine expression under diabetic conditions when compared to oxLDL (<xref rid="b9-mmr-14-04-3490" ref-type="bibr">9</xref>), which appears to contradict the results of the present <italic>in vitro</italic> study. The discrepancy between the <italic>in vitro</italic> and <italic>in vivo</italic> findings may be due to exogenous oxLDL/&#x003B2;2GPI acting as an antigen, which induced an auto-immune response and promoted the secretion of inflammatory molecules; however, this notion is required to be verified by further studies. The secretion of IL-1&#x003B2;, IL-6 and TNF-&#x003B1; stimulated by CRP/oxLDL and CRP/oxLDL/&#x003B2;2GPI was almost the same as that following stimulation with oxLDL; therefore, the two complexes can be regarded as pro-inflammatory agents.</p>
<p>Intracellular MAPK signaling cascades are important in the pathogenesis of cadiovascular diseases (<xref rid="b23-mmr-14-04-3490" ref-type="bibr">23</xref>). Three MAPK families (extracellular signal-regulated kinase 1/2, p38/MAPK and c-Jun N-terminal kinase) are signaling molecules that react to extracellular stimuli and regulate immune responses (<xref rid="b24-mmr-14-04-3490" ref-type="bibr">24</xref>). NF-&#x003BA;B activation has been linked with multiple aspects of biological functions, including inflammation, stress, cell proliferation, migration and tumour angiogenesis. A previous study by our group demonstrated that CRP/oxLDL/&#x003B2;2GPI increased the development and formation of AS lesions through the p38/MAPK signaling pathway in BALB/c mice (<xref rid="b9-mmr-14-04-3490" ref-type="bibr">9</xref>). Furthermore, andrographolide was indicated to reduce foam cell formation by blocking the p38/MAPK and NF-&#x003BA;B pathways in mouse peritoneal macrophages (<xref rid="b25-mmr-14-04-3490" ref-type="bibr">25</xref>). The present study explored the contribution of CRP/oxLDL/&#x003B2;2GPI complexes to the activation of p38/MAPK and NF-&#x003BA;B. The results revealed that p38/MAPK and NF-&#x003BA;B were involved in foam cell formation and inflammatory factor production induced by oxLDL and its complexes in RAW264.7 cells. The CRP/oxLDL complex mainly promoted the phosphorylation of p38MAPK, while CRP/oxLDL/&#x003B2;2GPI increased the phosphorylation of p38/MAPK as well as NF-&#x003BA;B <italic>in vitro</italic>. Hence, the induction of AS by CRP/oxLDL and CRP/oxLDL/&#x003B2;2GPI may be mediated via the activation of the p38MAPK and NF-&#x003BA;B pathways.</p>
<p>AS, which is a major health concern of worldwide importance, is a multifactorial process with not only lipoprotein metabolism but also inflammatory and immunological mechanisms linked to its initiation and progression (<xref rid="b26-mmr-14-04-3490" ref-type="bibr">26</xref>). oxLDL is an accepted key factor in macrophage lipid accumulation and foam cell establishment, leading to the formation of atherogenic lesions and plaques (<xref rid="b27-mmr-14-04-3490" ref-type="bibr">27</xref>). Circulating oxLDL has been reported to be a predictor of coronary disease in healthy middle-aged people, as well as in people with cardiovascular diseases and diabetes (<xref rid="b28-mmr-14-04-3490" ref-type="bibr">28</xref>,<xref rid="b29-mmr-14-04-3490" ref-type="bibr">29</xref>). While oxLDL alone is unstable in the blood circulation and is cleared rapidly, it is able to bind to &#x003B2;2GPI and/or CRP to form covalently stable complexes, which in turn trigger further pro-inflammatory and pro-atherogenic mechanisms.</p>
<p>Cu<sup>2+</sup>-oxLDL-derived ligands, such as 7-ketocholesteryl-9- carboxynonanoate, mediate the interaction with &#x003B2;2GPI through its positively charged V domain in a time- and temperature-dependent manner (<xref rid="b4-mmr-14-04-3490" ref-type="bibr">4</xref>). It has been confirmed that oxLDL/&#x003B2;2GPI is present in the blood circulation of patients with diseases, including systemic lupus erythematosus (SLE), APS, systemic sclerosis (<xref rid="b30-mmr-14-04-3490" ref-type="bibr">30</xref>), diabetes mellitus (DM) (<xref rid="b10-mmr-14-04-3490" ref-type="bibr">10</xref>) and chronic renal diseases (<xref rid="b31-mmr-14-04-3490" ref-type="bibr">31</xref>), as well as acute coronary syndromes (<xref rid="b32-mmr-14-04-3490" ref-type="bibr">32</xref>). OxLDL/&#x003B2;2GPI is regarded to be a pro-atherogenic auto-antigen accounting for pre-mature or accelerated arteriosclerotic cardiovascular disease in systemic auto-immune disease (<xref rid="b33-mmr-14-04-3490" ref-type="bibr">33</xref>). Anti-&#x003B2;2GPI antibodies accelerate macrophage uptake and accumulation of oxLDL in the presence of &#x003B2;2GPI <italic>in vitro</italic> (<xref rid="b34-mmr-14-04-3490" ref-type="bibr">34</xref>). OxLDL/&#x003B2;2GPI/anti-&#x003B2;2GPI was internalized by macrophages via anti-&#x003B2;2GPI antibody-mediated phagocytosis through Fc-&#x003B3;- and Toll-like receptors, suggesting that the uptake of oxLDL/&#x003B2;2GPI. CRP has a crucial role in the progression and vulnerability of AS lesions (<xref rid="b35-mmr-14-04-3490" ref-type="bibr">35</xref>) by inducing the production of cytokines and inflammatory mediators, including IL-1, IL-6, IL-8, TNF-&#x003B1;, intercellular adhesion molecule 1 and vascular cell adhesion molecule 1, which are involved in the development of AS depending on the activation of p38/MAPK, Akt and NF-&#x003BA;B (<xref rid="b36-mmr-14-04-3490" ref-type="bibr">36</xref>,<xref rid="b37-mmr-14-04-3490" ref-type="bibr">37</xref>). CRP binds to oxLDL by recognition of a phosphorylcholine moiety of oxLDL in a Ca<sup>2+</sup>- and pH-dependent manner, which is a regulated mechanism of macrophages to clear CRP (<xref rid="b7-mmr-14-04-3490" ref-type="bibr">7</xref>).</p>
<p>Unlike SLE and APS patients, in which oxLDL complexes and associated auto-antibodies are present, IgG auto-antibodies against oxLDL/&#x003B2;2GPI were merely observed in patients with non-autoimmune diseases, such as type 2 DM (<xref rid="b10-mmr-14-04-3490" ref-type="bibr">10</xref>). CRP/oxLDL and CRP/oxLDL/&#x003B2;2GPI complexes have been reported to be markedly elevated in patients with DM, rheumatoid arthritis and pyrogenic diseases, as compared with in healthy control subjects. Furthermore, the elevated complexes were reported to be associated with arterial inflammation and intima media thickness, suggesting that they may represent predictive markers with enhanced specificity for evaluating the severity of diabetic AS (<xref rid="b11-mmr-14-04-3490" ref-type="bibr">11</xref>). A recent study confirmed that patients with type 2 DM exhibited significantly higher serum levels of oxLDL/&#x003B2;2GPI complexes than age- and gender-matched healthy control subjects. Furthermore, serum oxLDL/&#x003B2;2GPI levels were correlated with the severity of coronary heart disease (<xref rid="b32-mmr-14-04-3490" ref-type="bibr">32</xref>).</p>
<p>The present study showed that oxLDL/&#x003B2;2GPI was able to repress macrophage phagocytosis of lipid and decrease the expression of inflammatory factors induced by oxLDL, which is consistent with a previous study by our group, which reported that &#x003B2;2GPI protects macrophages from oxLDL-induced foam-cell formation and apopotosis (<xref rid="b16-mmr-14-04-3490" ref-type="bibr">16</xref>). CRP/oxLDL and CRP/oxLDL/&#x003B2;2GPI exhibited a significant ability to induce foam-cell formation and activate inflammatory responses via p38MAPK and NF-&#x003BA;B phosphorylation, which was, however, decreased compared with that of oxLDL. CRP/oxLDL, oxLDL/&#x003B2;2GPI and CRP/oxLDL/&#x003B2;2GPI complexes can be distinguished from pyrogenic non-complexed CRP isoforms or unstable oxLDL and may therefore represent more specific and reliable predictive markers for AS. Thus, strategies aimed at detecting the complexes may prove to be beneficial in detecting and preventing atherothrombotic events in early stages. Among CRP/oxLDL, oxLDL/&#x003B2;2GPI and CRP/oxLDL/&#x003B2;2GPI, the complex which is most suitable as a predictive marker remains to be identified.</p>
<p>In conclusion, the present study indicated that CRP/oxLDL, oxLDL/&#x003B2;2GPI and CRP/oxLDL/&#x003B2;2GPI complexes induced the transformation of macrophages into foam cells by activating inflammatory responses via p38/MAPK and NF-&#x003BA;B signaling pathways. oxLDL/&#x003B2;2GPI had an anti-AS effect, but to a lesser extent than oxLDL alone. It may be possible that &#x003B2;2GPI has an anti-AS effect by forming a complex with oxLDL; however, this was not demonstrated in the present study. Due to their enhanced stability in the blood compared with oxLDL, complexes of oxLDL may be suitable as predictive biomarkers of AS.</p></sec></body>
<back>
<ack>
<title>Acknowledgments</title>
<p>The present study was supported by the National Natural Science Foundation of China (no. 81070645), The Key Projects in the Tianjin Science &amp; Technology Pillar Program (no. 13ZCZDSY01300), The Tianjin Natural Science Foundation (no. 10JCYBJC12000) and the Science and Technology Foundation of Tianjin Health Bureau (no. 2012KG135). The authors greatly appreciate the comprehensive and in-depth professional English language editing performed by Professor Gareth Denyer (School of Molecular Biosciences, Sydney University, Sydney, Australia).</p></ack>
<ref-list>
<title>References</title>
<ref id="b1-mmr-14-04-3490"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galkina</surname><given-names>E</given-names></name><name><surname>Ley</surname><given-names>K</given-names></name></person-group><article-title>Immune and inflammatory mechanisms of atherosclerosis (<sup>&#x0002A;</sup>)</article-title><source>Ann Rev Immunol</source><volume>27</volume><fpage>165</fpage><lpage>197</lpage><year>2009</year><pub-id pub-id-type="doi">10.1146/annurev.immunol.021908.132620</pub-id></element-citation></ref>
<ref id="b2-mmr-14-04-3490"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinecke</surname><given-names>JW</given-names></name></person-group><article-title>Mechanisms of oxidative damage of low density lipoprotein in human atherosclerosis</article-title><source>Curr Opin Lipidol</source><volume>8</volume><fpage>268</fpage><lpage>274</lpage><year>1997</year><pub-id pub-id-type="doi">10.1097/00041433-199710000-00005</pub-id><pub-id pub-id-type="pmid">9335950</pub-id></element-citation></ref>
<ref id="b3-mmr-14-04-3490"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyakis</surname><given-names>S</given-names></name><name><surname>Giannakopoulos</surname><given-names>B</given-names></name><name><surname>Krilis</surname><given-names>SA</given-names></name></person-group><article-title>Beta 2 glycoprotein I - function in health and disease</article-title><source>Thromb Res</source><volume>114</volume><fpage>335</fpage><lpage>346</lpage><year>2004</year><pub-id pub-id-type="doi">10.1016/j.thromres.2004.07.017</pub-id></element-citation></ref>
<ref id="b4-mmr-14-04-3490"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Matsuura</surname><given-names>E</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Furukawa</surname><given-names>J</given-names></name><name><surname>Kaihara</surname><given-names>K</given-names></name><name><surname>Inagaki</surname><given-names>J</given-names></name><name><surname>Atsumi</surname><given-names>T</given-names></name><name><surname>Sakairi</surname><given-names>N</given-names></name><name><surname>Yasuda</surname><given-names>T</given-names></name><name><surname>Voelker</surname><given-names>DR</given-names></name><name><surname>Koike</surname><given-names>T</given-names></name></person-group><article-title>A specific ligand for beta (2)-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages</article-title><source>J Lipid Res</source><volume>42</volume><fpage>697</fpage><lpage>709</lpage><year>2001</year><pub-id pub-id-type="pmid">11352976</pub-id></element-citation></ref>
<ref id="b5-mmr-14-04-3490"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Kishi</surname><given-names>M</given-names></name><name><surname>Atsumi</surname><given-names>T</given-names></name><name><surname>Bertolaccini</surname><given-names>ML</given-names></name><name><surname>Makino</surname><given-names>H</given-names></name><name><surname>Sakairi</surname><given-names>N</given-names></name><name><surname>Yamamoto</surname><given-names>I</given-names></name><name><surname>Yasuda</surname><given-names>T</given-names></name><name><surname>Khamashta</surname><given-names>MA</given-names></name><name><surname>Hughes</surname><given-names>GR</given-names></name><etal/></person-group><article-title>Circulating oxidized ldl forms complexes with beta2-glyco-protein I: Implication as an atherogenic autoantigen</article-title><source>J Lipid Res</source><volume>44</volume><fpage>716</fpage><lpage>726</lpage><year>2003</year><pub-id pub-id-type="doi">10.1194/jlr.M200329-JLR200</pub-id><pub-id pub-id-type="pmid">12562869</pub-id></element-citation></ref>
<ref id="b6-mmr-14-04-3490"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Ridker</surname><given-names>PM</given-names></name></person-group><article-title>Inflammation and atherosclerosis: Role of c-reactive protein in risk assessment</article-title><source>Am J Med</source><volume>116</volume><issue>Suppl 6A</issue><fpage>9S</fpage><lpage>16S</lpage><year>2004</year><pub-id pub-id-type="doi">10.1016/j.amjmed.2004.02.006</pub-id><pub-id pub-id-type="pmid">15050187</pub-id></element-citation></ref>
<ref id="b7-mmr-14-04-3490"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>MK</given-names></name><name><surname>Binder</surname><given-names>CJ</given-names></name><name><surname>Torzewski</surname><given-names>M</given-names></name><name><surname>Witztum</surname><given-names>JL</given-names></name></person-group><article-title>C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids</article-title><source>Proc Natl Acad Sci USA</source><volume>99</volume><fpage>13043</fpage><lpage>13048</lpage><year>2002</year><pub-id pub-id-type="doi">10.1073/pnas.192399699</pub-id><pub-id pub-id-type="pmid">12244213</pub-id><pub-id pub-id-type="pmcid">130583</pub-id></element-citation></ref>
<ref id="b8-mmr-14-04-3490"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuura</surname><given-names>E</given-names></name><name><surname>Kobayashia</surname><given-names>K</given-names></name><name><surname>Koikeb</surname><given-names>T</given-names></name><name><surname>Shoenfeld</surname><given-names>Y</given-names></name><name><surname>Khamashta</surname><given-names>MA</given-names></name><name><surname>Hughes</surname><given-names>GR</given-names></name></person-group><article-title>Atherogenic autoantigen: Oxidized LDL complexes with beta2-glycoprotein I</article-title><source>Immunobiology</source><volume>207</volume><fpage>17</fpage><lpage>22</lpage><year>2003</year><pub-id pub-id-type="doi">10.1078/0171-2985-00214</pub-id><pub-id pub-id-type="pmid">12638898</pub-id></element-citation></ref>
<ref id="b9-mmr-14-04-3490"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Zhou</surname><given-names>SJ</given-names></name><name><surname>Li</surname><given-names>CJ</given-names></name><name><surname>Wang</surname><given-names>XN</given-names></name><name><surname>Tang</surname><given-names>YZ</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Lv</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Xing</surname><given-names>QL</given-names></name><name><surname>Yu</surname><given-names>DM</given-names></name><name><surname>Yu</surname><given-names>P</given-names></name></person-group><article-title>C-reactive protein/oxidised low-density lipoprotein/&#x003B2;2-glycoprotein I complex promotes atherosclerosis in diabetic BALB/c mice via p38mitogen-activated protein kinase signal pathway</article-title><source>Lipids Health Dis</source><volume>12</volume><fpage>42</fpage><year>2013</year><pub-id pub-id-type="doi">10.1186/1476-511X-12-42</pub-id></element-citation></ref>
<ref id="b10-mmr-14-04-3490"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez</surname><given-names>LR</given-names></name><name><surname>Hurley</surname><given-names>BL</given-names></name><name><surname>Simpson</surname><given-names>DF</given-names></name><name><surname>Matsuura</surname><given-names>E</given-names></name></person-group><article-title>Oxidized low-density lipoprotein/beta2-glycoprotein I complexes and autoantibodies in patients with type 2 diabetes mellitus</article-title><source>Ann NY Acad Sci</source><volume>1051</volume><fpage>97</fpage><lpage>103</lpage><year>2005</year><pub-id pub-id-type="doi">10.1196/annals.1361.050</pub-id><pub-id pub-id-type="pmid">16126948</pub-id></element-citation></ref>
<ref id="b11-mmr-14-04-3490"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabuchi</surname><given-names>M</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><name><surname>Usui-Kataoka</surname><given-names>H</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Teramoto</surname><given-names>M</given-names></name><name><surname>Takasugi</surname><given-names>K</given-names></name><name><surname>Shikata</surname><given-names>K</given-names></name><name><surname>Yamamura</surname><given-names>M</given-names></name><name><surname>Ando</surname><given-names>K</given-names></name><name><surname>Nishida</surname><given-names>K</given-names></name><etal/></person-group><article-title>The association of c-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis</article-title><source>J Lipid Res</source><volume>48</volume><fpage>768</fpage><lpage>781</lpage><year>2007</year><pub-id pub-id-type="doi">10.1194/jlr.M600414-JLR200</pub-id><pub-id pub-id-type="pmid">17261875</pub-id></element-citation></ref>
<ref id="b12-mmr-14-04-3490"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meuwissen</surname><given-names>M</given-names></name><name><surname>van der Wal</surname><given-names>AC</given-names></name><name><surname>Niessen</surname><given-names>HW</given-names></name><name><surname>Koch</surname><given-names>KT</given-names></name><name><surname>de Winter</surname><given-names>RJ</given-names></name><name><surname>van der Loos</surname><given-names>CM</given-names></name><name><surname>Rittersma</surname><given-names>SZ</given-names></name><name><surname>Chamuleau</surname><given-names>SA</given-names></name><name><surname>Tijssen</surname><given-names>JG</given-names></name><name><surname>Becker</surname><given-names>AE</given-names></name><name><surname>Piek</surname><given-names>JJ</given-names></name></person-group><article-title>Colocalisation of intraplaque C reactive protein, complement, oxidised low density lipoprotein, and macrophages in stable and unstable angina and acute myocardial infarction</article-title><source>J Clin Pathol</source><volume>59</volume><fpage>196</fpage><lpage>201</lpage><year>2006</year><pub-id pub-id-type="doi">10.1136/jcp.2005.027235</pub-id><pub-id pub-id-type="pmid">16443738</pub-id><pub-id pub-id-type="pmcid">1860312</pub-id></element-citation></ref>
<ref id="b13-mmr-14-04-3490"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>JL</given-names></name><name><surname>Basu</surname><given-names>SK</given-names></name><name><surname>Brown</surname><given-names>MS</given-names></name></person-group><article-title>Receptor-mediated endocytosis of low-density lipoprotein in cultured cells</article-title><source>Methods Enzymol</source><volume>98</volume><fpage>241</fpage><lpage>260</lpage><year>1983</year><pub-id pub-id-type="doi">10.1016/0076-6879(83)98152-1</pub-id><pub-id pub-id-type="pmid">6321901</pub-id></element-citation></ref>
<ref id="b14-mmr-14-04-3490"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laplante</surname><given-names>P</given-names></name><name><surname>Amireault</surname><given-names>P</given-names></name><name><surname>Subang</surname><given-names>R</given-names></name><name><surname>Dieud&#x000E9;</surname><given-names>M</given-names></name><name><surname>Levine</surname><given-names>JS</given-names></name><name><surname>Rauch</surname><given-names>J</given-names></name></person-group><article-title>Interaction of &#x003B2;2-glycoprotein I with lipopolysaccharide leads to Toll-like receptor 4 (TLR4)-dependent activation of macrophages</article-title><source>J Biol Chem</source><volume>286</volume><fpage>42494</fpage><lpage>42503</lpage><year>2011</year><pub-id pub-id-type="doi">10.1074/jbc.M111.230383</pub-id><pub-id pub-id-type="pmid">21965665</pub-id><pub-id pub-id-type="pmcid">3234909</pub-id></element-citation></ref>
<ref id="b15-mmr-14-04-3490"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Furukawa</surname><given-names>J</given-names></name><name><surname>Inagaki</surname><given-names>J</given-names></name><name><surname>Sakairi</surname><given-names>N</given-names></name><name><surname>Iwado</surname><given-names>A</given-names></name><name><surname>Yasuda</surname><given-names>T</given-names></name><name><surname>Koike</surname><given-names>T</given-names></name><name><surname>Voelker</surname><given-names>DR</given-names></name><name><surname>Matsuura</surname><given-names>E</given-names></name></person-group><article-title>Omega-carboxyl variants of 7-ketocholesteryl esters are ligands for beta (2)-glycoprotein I and mediate antibody-dependent uptake of oxidized ldl by macrophages</article-title><source>J Lipid Res</source><volume>43</volume><fpage>1486</fpage><lpage>1495</lpage><year>2002</year><pub-id pub-id-type="doi">10.1194/jlr.M20063-JLR200</pub-id><pub-id pub-id-type="pmid">12235181</pub-id></element-citation></ref>
<ref id="b16-mmr-14-04-3490"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>WL</given-names></name><name><surname>Meng</surname><given-names>ZX</given-names></name><name><surname>Zhou</surname><given-names>SJ</given-names></name><name><surname>Li</surname><given-names>CJ</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Lv</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>ZJ</given-names></name><name><surname>Yu</surname><given-names>DM</given-names></name><name><surname>Yu</surname><given-names>P</given-names></name></person-group><article-title>Reduced beta2-glycoprotein I protects macrophages from ox-LDL-induced foam cell formation and cell apoptosis</article-title><source>Lipids Health Dis</source><volume>12</volume><fpage>174</fpage><year>2013</year><pub-id pub-id-type="doi">10.1186/1476-511X-12-174</pub-id><pub-id pub-id-type="pmid">24238298</pub-id><pub-id pub-id-type="pmcid">3842777</pub-id></element-citation></ref>
<ref id="b17-mmr-14-04-3490"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>SR</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Potempa</surname><given-names>LA</given-names></name><name><surname>Qiu</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name></person-group><article-title>Interactions of C-reactive protein with low-density lipoproteins: Implications for an active role of modified C-reactive protein in atherosclerosis</article-title><source>Int J Biochem Cell Biol</source><volume>38</volume><fpage>648</fpage><lpage>661</lpage><year>2006</year><pub-id pub-id-type="doi">10.1016/j.biocel.2005.11.004</pub-id></element-citation></ref>
<ref id="b18-mmr-14-04-3490"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>MK</given-names></name><name><surname>Hartvigsen</surname><given-names>K</given-names></name><name><surname>Ryu</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>KH</given-names></name></person-group><article-title>The pro-atherogenic effects of macrophages are reduced upon formation of a complex between C-reactive protein and lysophosphatidylcholine</article-title><source>J Inflamm (Lond)</source><volume>9</volume><fpage>42</fpage><year>2012</year><pub-id pub-id-type="doi">10.1186/1476-9255-9-42</pub-id></element-citation></ref>
<ref id="b19-mmr-14-04-3490"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>KJ</given-names></name><name><surname>Freeman</surname><given-names>MW</given-names></name></person-group><article-title>Scavenger receptors in atherosclerosis: Beyond lipid uptake</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>26</volume><fpage>1702</fpage><lpage>1711</lpage><year>2006</year><pub-id pub-id-type="doi">10.1161/01.ATV.0000229218.97976.43</pub-id><pub-id pub-id-type="pmid">16728653</pub-id></element-citation></ref>
<ref id="b20-mmr-14-04-3490"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Collins</surname><given-names>HL</given-names></name><name><surname>Ranalletta</surname><given-names>M</given-names></name><name><surname>Fuki</surname><given-names>IV</given-names></name><name><surname>Billheimer</surname><given-names>JT</given-names></name><name><surname>Rothblat</surname><given-names>GH</given-names></name><name><surname>Tall</surname><given-names>AR</given-names></name><name><surname>Rader</surname><given-names>DJ</given-names></name></person-group><article-title>Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo</article-title><source>J Clin Invest</source><volume>117</volume><fpage>2216</fpage><lpage>2224</lpage><year>2007</year><pub-id pub-id-type="doi">10.1172/JCI32057</pub-id><pub-id pub-id-type="pmid">17657311</pub-id><pub-id pub-id-type="pmcid">1924499</pub-id></element-citation></ref>
<ref id="b21-mmr-14-04-3490"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuura</surname><given-names>E</given-names></name><name><surname>Atzeni</surname><given-names>F</given-names></name><name><surname>Sarzi-Puttini</surname><given-names>P</given-names></name><name><surname>Turiel</surname><given-names>M</given-names></name><name><surname>Lopez</surname><given-names>LR</given-names></name><name><surname>Nurmohamed</surname><given-names>MT</given-names></name></person-group><article-title>Is atherosclerosis an autoimmune disease?</article-title><source>BMC Med</source><volume>12</volume><fpage>47</fpage><year>2014</year><pub-id pub-id-type="doi">10.1186/1741-7015-12-47</pub-id><pub-id pub-id-type="pmid">24642015</pub-id><pub-id pub-id-type="pmcid">3984678</pub-id></element-citation></ref>
<ref id="b22-mmr-14-04-3490"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinarello</surname><given-names>CA</given-names></name></person-group><article-title>Interleukin-1 in the pathogenesis and treatment of inflammatory diseases</article-title><source>Blood</source><volume>117</volume><fpage>3720</fpage><lpage>3732</lpage><year>2011</year><pub-id pub-id-type="doi">10.1182/blood-2010-07-273417</pub-id><pub-id pub-id-type="pmid">21304099</pub-id><pub-id pub-id-type="pmcid">3083294</pub-id></element-citation></ref>
<ref id="b23-mmr-14-04-3490"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muslin</surname><given-names>AJ</given-names></name></person-group><article-title>MAPK signalling in cardiovascular health and disease: Molecular mechanisms and therapeutic targets</article-title><source>Clin Sci (Lond)</source><volume>115</volume><fpage>203</fpage><lpage>218</lpage><year>2008</year><pub-id pub-id-type="doi">10.1042/CS20070430</pub-id></element-citation></ref>
<ref id="b24-mmr-14-04-3490"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearson</surname><given-names>G</given-names></name><name><surname>Robinson</surname><given-names>F</given-names></name><name><surname>Beers Gibson</surname><given-names>T</given-names></name><name><surname>Xu</surname><given-names>BE</given-names></name><name><surname>Karandikar</surname><given-names>M</given-names></name><name><surname>Berman</surname><given-names>K</given-names></name><name><surname>Cobb</surname><given-names>MH</given-names></name></person-group><article-title>Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions</article-title><source>Endocr Rev</source><volume>22</volume><fpage>153</fpage><lpage>183</lpage><year>2001</year><pub-id pub-id-type="pmid">11294822</pub-id></element-citation></ref>
<ref id="b25-mmr-14-04-3490"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>FX</given-names></name><name><surname>Li</surname><given-names>SS</given-names></name></person-group><article-title>Effects of andrographolide on the activation of mitogen activated protein kinases and nuclear factor-&#x003BA;B in mouse peritoneal macrophage-derived foam cells</article-title><source>Chin J Integr Med</source><volume>18</volume><fpage>391</fpage><lpage>394</lpage><year>2012</year><pub-id pub-id-type="doi">10.1007/s11655-011-0700-8</pub-id></element-citation></ref>
<ref id="b26-mmr-14-04-3490"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>C</given-names></name><name><surname>Noels</surname><given-names>H</given-names></name></person-group><article-title>Atherosclerosis: Current pathogenesis and therapeutic options</article-title><source>Nat Med</source><volume>17</volume><fpage>1410</fpage><lpage>1422</lpage><year>2011</year><pub-id pub-id-type="doi">10.1038/nm.2538</pub-id><pub-id pub-id-type="pmid">22064431</pub-id></element-citation></ref>
<ref id="b27-mmr-14-04-3490"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Lopez</surname><given-names>LR</given-names></name><name><surname>Shoenfeld</surname><given-names>Y</given-names></name><name><surname>Matsuura</surname><given-names>E</given-names></name></person-group><article-title>The role of innate and adaptive immunity to oxidized low-density lipoprotein in the development of atherosclerosis</article-title><source>Ann NY Acad Sci</source><volume>1051</volume><fpage>442</fpage><lpage>454</lpage><year>2005</year><pub-id pub-id-type="doi">10.1196/annals.1361.086</pub-id><pub-id pub-id-type="pmid">16126986</pub-id></element-citation></ref>
<ref id="b28-mmr-14-04-3490"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meisinger</surname><given-names>C</given-names></name><name><surname>Baumert</surname><given-names>J</given-names></name><name><surname>Khuseyinova</surname><given-names>N</given-names></name><name><surname>Loewel</surname><given-names>H</given-names></name><name><surname>Koenig</surname><given-names>W</given-names></name></person-group><article-title>Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population</article-title><source>Circulation</source><volume>112</volume><fpage>651</fpage><lpage>657</lpage><year>2005</year><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.104.529297</pub-id><pub-id pub-id-type="pmid">16043640</pub-id></element-citation></ref>
<ref id="b29-mmr-14-04-3490"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuzura</surname><given-names>S</given-names></name><name><surname>Ikeda</surname><given-names>Y</given-names></name><name><surname>Suehiro</surname><given-names>T</given-names></name><name><surname>Ota</surname><given-names>K</given-names></name><name><surname>Osaki</surname><given-names>F</given-names></name><name><surname>Arii</surname><given-names>K</given-names></name><name><surname>Kumon</surname><given-names>Y</given-names></name><name><surname>Hashimoto</surname><given-names>K</given-names></name></person-group><article-title>Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes</article-title><source>Metabolism</source><volume>53</volume><fpage>297</fpage><lpage>302</lpage><year>2004</year><pub-id pub-id-type="doi">10.1016/j.metabol.2003.10.009</pub-id><pub-id pub-id-type="pmid">15015140</pub-id></element-citation></ref>
<ref id="b30-mmr-14-04-3490"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez</surname><given-names>LR</given-names></name><name><surname>Simpson</surname><given-names>DF</given-names></name><name><surname>Hurley</surname><given-names>BL</given-names></name><name><surname>Matsuura</surname><given-names>E</given-names></name></person-group><article-title>OxLDL/beta2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis and antiphospholipid syndrome: Pathogenic implications for vascular involvement</article-title><source>Ann NY Acad Sci</source><volume>1051</volume><fpage>313</fpage><lpage>322</lpage><year>2005</year><pub-id pub-id-type="doi">10.1196/annals.1361.073</pub-id></element-citation></ref>
<ref id="b31-mmr-14-04-3490"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasahara</surname><given-names>J</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Maeshima</surname><given-names>Y</given-names></name><name><surname>Yamasaki</surname><given-names>Y</given-names></name><name><surname>Yasuda</surname><given-names>T</given-names></name><name><surname>Matsuura</surname><given-names>E</given-names></name><name><surname>Makino</surname><given-names>H</given-names></name></person-group><article-title>Clinical significance of serum oxidized low-density lipoprotein/beta2-glycoprotein I complexes in patients with chronic renal diseases</article-title><source>Nephron Clin Pract</source><volume>98</volume><fpage>c15</fpage><lpage>c24</lpage><year>2004</year><pub-id pub-id-type="doi">10.1159/000079923</pub-id><pub-id pub-id-type="pmid">15361700</pub-id></element-citation></ref>
<ref id="b32-mmr-14-04-3490"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greco</surname><given-names>TP</given-names></name><name><surname>Conti-Kelly</surname><given-names>AM</given-names></name><name><surname>Anthony</surname><given-names>JR</given-names></name><name><surname>Greco</surname><given-names>TJ</given-names></name><name><surname>Doyle</surname><given-names>R</given-names></name><name><surname>Boisen</surname><given-names>M</given-names></name><name><surname>Kojima</surname><given-names>K</given-names></name><name><surname>Matsuura</surname><given-names>E</given-names></name><name><surname>Lopez</surname><given-names>LR</given-names></name></person-group><article-title>Oxidized-LDL/beta (2)-glycoprotein I complexes are associated with disease severity and increased risk for adverse outcomes in patients with acute coronary syndromes</article-title><source>Am J Clin Pathol</source><volume>133</volume><fpage>737</fpage><lpage>743</lpage><year>2010</year><pub-id pub-id-type="doi">10.1309/AJCP88WVRDRDFBAS</pub-id><pub-id pub-id-type="pmid">20395520</pub-id></element-citation></ref>
<ref id="b33-mmr-14-04-3490"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherer</surname><given-names>Y</given-names></name><name><surname>Shoenfeld</surname><given-names>Y</given-names></name></person-group><article-title>Mechanisms of disease: Atherosclerosis in autoimmune diseases</article-title><source>Nat Clin Pract Rheumatol</source><volume>2</volume><fpage>99</fpage><lpage>106</lpage><year>2006</year><pub-id pub-id-type="doi">10.1038/ncprheum0092</pub-id><pub-id pub-id-type="pmid">16932663</pub-id></element-citation></ref>
<ref id="b34-mmr-14-04-3490"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>H</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name></person-group><article-title>OxLDL/&#x003B2;2GPI/anti-&#x003B2;2GPI complex induced macrophage differentiation to foam cell involving TLR4/NF-KappaB signal transduction pathway</article-title><source>Thromb Res</source><volume>134</volume><fpage>384</fpage><lpage>392</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.thromres.2014.05.017</pub-id><pub-id pub-id-type="pmid">24882274</pub-id></element-citation></ref>
<ref id="b35-mmr-14-04-3490"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>KH</given-names></name><name><surname>Hong</surname><given-names>KH</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Ko</surname><given-names>J</given-names></name><name><surname>Kang</surname><given-names>DH</given-names></name><name><surname>Choi</surname><given-names>KJ</given-names></name><name><surname>Hong</surname><given-names>MK</given-names></name><name><surname>Park</surname><given-names>SW</given-names></name><name><surname>Park</surname><given-names>SJ</given-names></name></person-group><article-title>C-reactive protein promotes monocyte chemoattractant protein-1-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes</article-title><source>Circulation</source><volume>109</volume><fpage>2566</fpage><lpage>2571</lpage><year>2004</year><pub-id pub-id-type="doi">10.1161/01.CIR.0000131160.94926.6E</pub-id><pub-id pub-id-type="pmid">15136507</pub-id></element-citation></ref>
<ref id="b36-mmr-14-04-3490"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devaraj</surname><given-names>S</given-names></name><name><surname>Kumaresan</surname><given-names>PR</given-names></name><name><surname>Jialal</surname><given-names>I</given-names></name></person-group><article-title>Effect of C-reactive protein on chemokine expression in human aortic endothelial cells</article-title><source>J Mol Cell Cardiol</source><volume>36</volume><fpage>405</fpage><lpage>410</lpage><year>2004</year><pub-id pub-id-type="doi">10.1016/j.yjmcc.2003.12.005</pub-id><pub-id pub-id-type="pmid">15010279</pub-id></element-citation></ref>
<ref id="b37-mmr-14-04-3490"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galve-de Rochemonteix</surname><given-names>B</given-names></name><name><surname>Wiktorowicz</surname><given-names>K</given-names></name><name><surname>Kushner</surname><given-names>I</given-names></name><name><surname>Dayer</surname><given-names>JM</given-names></name></person-group><article-title>C-reactive protein increases production of IL-1 alpha, IL-1 beta and TNF-alpha, and expression of mRNA by human alveolar macrophages</article-title><source>J Leukoc Biol</source><volume>53</volume><fpage>439</fpage><lpage>445</lpage><year>1993</year><pub-id pub-id-type="pmid">8482924</pub-id></element-citation></ref></ref-list></back>
<floats-group>
<fig id="f1-mmr-14-04-3490" position="float">
<label>Figure 1</label>
<caption>
<p>Lipid deposition in of RAW264.7 macrophages visualized by Oil red O staining (magnification, &#x000D7;320). Representative images of control, CPR, &#x003B2;2GPI, oxLDL, CRP/oxLDL, oxLDL/&#x003B2;2GPI and CRP/oxLDL/&#x003B2;2GPI groups. oxLDL, oxidized lipopolysaccharide; CRP, C-reactive protein; &#x003B2;2GPI, &#x003B2;2-glycoprotein I.</p></caption>
<graphic xlink:href="MMR-14-04-3490-g00.jpg"/></fig>
<fig id="f2-mmr-14-04-3490" position="float">
<label>Figure 2</label>
<caption>
<p>Effects of CRP/oxLDL/&#x003B2;2GPI complexes on CD36, SRB1 and ABCA1, ABCG1 mRNA expression in RAW264.7 macrophages. The mRNA expression of (A) CD36, (B) SRB1, (C) ABCA1 and (D) ABCG1 in the experimental groups was determined by reverse-transcription quantitative polymerase chain reaction analysis. Values were normalized to &#x003B2;-actin using the 2<sup>&#x02212;&#x00394;&#x00394;Ct</sup> method. Values are expressed as the mean &#x000B1; standard deviation of experiments performed three times in duplicate. <sup>&#x022C6;</sup>P&lt;0.05, compared with control group; <sup>#</sup>P&lt;0.05, compared with oxLDL group. oxLDL, oxidized lipopolysaccharide; CRP, C-reactive protein; &#x003B2;2GPI, &#x003B2;2-glycoprotein I.</p></caption>
<graphic xlink:href="MMR-14-04-3490-g01.jpg"/></fig>
<fig id="f3-mmr-14-04-3490" position="float">
<label>Figure 3</label>
<caption>
<p>Effects of CRP/oxLDL/&#x003B2;2GPI complexes on the expression of inflammatory factors IL-1&#x003B2;, IL-6 and TNF-&#x003B1;. After treatment with CPR, &#x003B2;2GPI, oxLDL, CRP/oxLDL, oxLDL/&#x003B2;2GPI or CRP/oxLDL/&#x003B2;2GPI for 24 h, culture media of RAW264.7 macrophages were collected. The levels of IL-1&#x003B2;, IL-6 and TNF-&#x003B1; were measured using commercial ELISA kits. Values are expressed as the mean &#x000B1; standard deviation of experiments performed three times in duplicate. <sup>&#x022C6;</sup>P&lt;0.05, compared with control group; <sup>#</sup>P&lt;0.05, compared with oxLDL group. oxLDL, oxidized lipopolysaccharide; CRP, C-reactive protein; &#x003B2;2GPI, &#x003B2;2-glycoprotein I. TNF, tumor necrosis factor; IL, interleukin.</p></caption>
<graphic xlink:href="MMR-14-04-3490-g02.jpg"/></fig>
<fig id="f4-mmr-14-04-3490" position="float">
<label>Figure 4</label>
<caption>
<p>Effects of CRP/oxLDL/&#x003B2;2GPI complexes on p38/MAPK and NF-&#x003BA;B phosphorylation in RAW264.7 macrophages. Phosphorylated and total (A) p38/MAPK and (B) NF-&#x003BA;B were determined by western blot analysis. Immunoreactive bands were quantified by grey value analysis normalized to &#x003B2;-actin. Values are expressed as the mean &#x000B1; standard deviation of experiments performed three times in duplicate. <sup>&#x022C6;</sup>P&lt;0.05, compared with control group; <sup>#</sup>P&lt;0.05, compared with oxLDL group. oxLDL, oxidized lipopolysaccharide; CRP, C-reactive protein; &#x003B2;2GPI, &#x003B2;2-glycoprotein I; MAPK, mitogen-activated protein kinase; p-NF-&#x003BA;B, phosphorylated nuclear factor kappa B.</p></caption>
<graphic xlink:href="MMR-14-04-3490-g03.jpg"/></fig>
<table-wrap id="tI-mmr-14-04-3490" position="float">
<label>Table I</label>
<caption>
<p>Effects of CRP/oxLDL/&#x003B2;2GPI complexes on intracellular TC content in RAW264.7 macrophages.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="top" align="left">Group</th>
<th valign="top" align="center">TC concentration<break/>(<italic>&#x000B5;</italic>mol/mg protein)</th></tr></thead>
<tbody>
<tr>
<td valign="top" align="left">Control</td>
<td valign="top" align="center">22.6&#x000B1;3.1</td></tr>
<tr>
<td valign="top" align="left">CRP</td>
<td valign="top" align="center">26.0&#x000B1;4.7<xref rid="tfn3-mmr-14-04-3490" ref-type="table-fn">b</xref></td></tr>
<tr>
<td valign="top" align="left">&#x003B2;2GPI</td>
<td valign="top" align="center">20.3&#x000B1;2.5<xref rid="tfn3-mmr-14-04-3490" ref-type="table-fn">b</xref></td></tr>
<tr>
<td valign="top" align="left">oxLDL</td>
<td valign="top" align="center">151.4&#x000B1;6.2<xref rid="tfn2-mmr-14-04-3490" ref-type="table-fn">a</xref></td></tr>
<tr>
<td valign="top" align="left">CRP/oxLDL</td>
<td valign="top" align="center">124.3&#x000B1;4.0<xref rid="tfn2-mmr-14-04-3490" ref-type="table-fn">a</xref>,<xref rid="tfn3-mmr-14-04-3490" ref-type="table-fn">b</xref></td></tr>
<tr>
<td valign="top" align="left">oxLDL/&#x003B2;2GPI</td>
<td valign="top" align="center">70.4&#x000B1;3.9<xref rid="tfn2-mmr-14-04-3490" ref-type="table-fn">a</xref>,<xref rid="tfn3-mmr-14-04-3490" ref-type="table-fn">b</xref></td></tr>
<tr>
<td valign="top" align="left">CRP/oxLDL/&#x003B2;2GPI</td>
<td valign="top" align="center">91.2&#x000B1;5.8<xref rid="tfn2-mmr-14-04-3490" ref-type="table-fn">a</xref>,<xref rid="tfn3-mmr-14-04-3490" ref-type="table-fn">b</xref></td></tr></tbody></table>
<table-wrap-foot><fn id="tfn1-mmr-14-04-3490">
<p>Values are expressed as the mean &#x000B1; standard deviation of experiments performed three times in duplicate.</p></fn><fn id="tfn2-mmr-14-04-3490">
<label>a</label>
<p>P&lt;0.05, compared with control group;</p></fn><fn id="tfn3-mmr-14-04-3490">
<label>b</label>
<p>P&lt;0.05, compared with oxLDL group. TC, total cholesterol; oxLDL, oxidized lipopolysaccharide; CRP, C-reactive protein; &#x003B2;2GPI, &#x003B2;2-glycoprotein I.</p></fn></table-wrap-foot></table-wrap></floats-group></article>
